Ocular diseases have a significant effect on vision and quality of life. Drug delivery to ocular
tissues is a challenge to formulation scientists. The major barriers to delivering drugs to the …

When administering eye drops, even when completely correctly applied, several routes of
absorption are possible and excess amounts can sometimes cause an unwanted systemic …

The etiology of dry eye disease (DED) is complex and not yet fully understood, but the
disease is now recognized as being associated with ocular surface inflammation. The latest …

Introduction Ocular barriers hinder drug delivery and reduce drug bioavailability. This article
focuses on enhancing drug absorption across the corneal and conjunctival epithelium. Both …

Hybrid or recombinant protein-polymers, peptide-based biomaterials, and antibody-targeted
therapeutics are widely explored for various ocular conditions and vision correction. They …

Latanoprostene bunod (LBN) is a topical ophthalmic therapeutic for the reduction of
intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension …

Ocular hypertension due to increased intraocular pressure is a major risk factor for the
development of glaucoma. Rapid clearance and low ocular bioavailability are drawbacks of …

Topical drug administration for back of the eye delivery is extremely challenging due to the
presence of protection mechanisms and physiological barriers. Self-assembled polymeric …

Over the past decade, there has been a rise in the number of clinical cases of moderate to
severe anterior segment ocular diseases. Conventional topical ophthalmic formulations …

To improve the ocular bioavailability of the model drug of pirenoxine sodium (PRN), organic-
inorganic hybrid nanocomposites including layered double hydroxides (LDH) and chitosan …